Jonathan Yen-Wen Yu Sells 8,796 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 8,796 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total value of $731,123.52. Following the transaction, the chief operating officer owned 54,324 shares in the company, valued at $4,515,410.88. This trade represents a 13.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Monday, August 24th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $82.53, for a total value of $24,759.00.
• On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The shares were sold at an average price of $82.64, for a total value of $66,442.56.
• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The stock was sold at an average price of $82.50, for a total value of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $72.50, for a total value of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total value of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Stock Down 0.1%

Shares of NASDAQ:IRON opened at $82.55 on Friday. The firm has a market capitalization of $316.58 million, a PE ratio of -12.55 and a beta of 1.00. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The firm’s 50-day moving average is $76.79 and its two-hundred day moving average is $69.97.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, beating the consensus estimate of ($1.71) by $0.17. Analysts predict that Disc Medicine, Inc. will post -6.61 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on IRON. Wall Street Zen upgraded shares of Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Morgan Stanley reiterated an “overweight” rating and issued a $90.00 price objective on shares of Disc Medicine in a research note on Monday, August 17th. Wedbush reissued an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research note on Wednesday, June 10th. HC Wainwright upped their price target on Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.50.

Institutional Investors Weigh In On Disc Medicine

A number of large investors have recently modified their holdings of IRON. Arizona State Retirement System raised its holdings in shares of Disc Medicine by 2.2% in the 4th quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock valued at $540,000 after purchasing an additional 144 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Disc Medicine by 3.3% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after purchasing an additional 215 shares in the last quarter. AlphaCentric Advisors LLC grew its stake in shares of Disc Medicine by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock worth $254,000 after purchasing an additional 216 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in Disc Medicine by 3.3% in the fourth quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock valued at $740,000 after buying an additional 296 shares during the last quarter. Finally, State of Wyoming purchased a new position in shares of Disc Medicine in the 2nd quarter valued at about $25,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.